Content about treatment of autoimmune disorders

September 10, 2013

European regulators have approved the European Union's first biosimilar monoclonal antibody. The new product, made by U.S.-based Hospira, comes seven years after the approval of Europe's first biosimilar.

LEAMINGTON SPA, United Kingdom — European regulators have approved the European Union's first biosimilar monoclonal antibody. The new product, made by U.S.-based Hospira, comes seven years after the approval of Europe's first biosimilar.

Hospira announced Tuesday the European Medicines Agency's approval of Inflectra (infliximab) for the treatment of autoimmune disorders like rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriatic arthritis and psoriasis.

March 11, 2013

Early detection of a deadly brain infection that sometimes arises due to treatment of autoimmune disorders with immune-suppressing biotech drugs may improve survival, according to a new study.

SAN DIEGO — Early detection of a deadly brain infection that sometimes arises due to treatment of autoimmune disorders with immune-suppressing biotech drugs may improve survival, according to a new study.

The study, released Sunday and scheduled for presentation at the 65th annual meeting of the American Academy of Neurology in San Diego, which starts next Saturday, found that early detection of progressive multifocal leukoencephalopathy, or PML, may improve survival and disability levels.